Name: Building a Better Backbone for NSCLC and SCLC Treatment With PD-(L)1xVEGF-A Bispecific Antibodies: Inducing Immune Invigoration, Simplifying Treatment Delivery, and Enhancing Clinical Outcomes
Start: 2026-09-13T18:15:00+09:00
End: 2026-09-13T19:15:00+09:00

Sign up for news updates

Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

Building a Better Backbone for NSCLC and SCLC Treatment With PD-(L)1xVEGF-A Bispecific Antibodies: Inducing Immune Invigoration, Simplifying Treatment Delivery, and Enhancing Clinical Outcomes

Details